S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Greek authorities rescue 91 migrants from river islet on border with Turkey
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Greek authorities rescue 91 migrants from river islet on border with Turkey
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Greek authorities rescue 91 migrants from river islet on border with Turkey
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Greek authorities rescue 91 migrants from river islet on border with Turkey
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
NASDAQ:ALBO

Albireo Pharma (ALBO) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$43.99
$44.90
50-Day Range
$43.50
$44.95
52-Week Range
$16.02
$45.23
Volume
1.24 million shs
Average Volume
704,539 shs
Market Capitalization
$913.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.00

Albireo Pharma MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
8.7% Upside
$48.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.53
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($7.86) to ($6.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.24 out of 5 stars

Medical Sector

943rd out of 980 stocks

Pharmaceutical Preparations Industry

467th out of 485 stocks


ALBO stock logo

About Albireo Pharma (NASDAQ:ALBO) Stock

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALBO Stock News Headlines

Our #1 Laser Stock for May
The Pentagon calls laser weapons "the future." This small cap just won a $1.65 billion contract to make them. See why this stock could soar 2,476% >>>
ALBO Albireo Pharma, Inc.
Albireo Pharma, Inc. (ALBO)
Our #1 Laser Stock for May
The Pentagon calls laser weapons "the future." This small cap just won a $1.65 billion contract to make them. See why this stock could soar 2,476% >>>
ALBO.PH - | Stock Price & Latest News | Reuters
Why These Two Biotech Stocks Blasted Higher This Week
Expert Ratings for Albireo Pharma
See More Headlines


ALBO Company Calendar

Last Earnings
11/04/2021
Today
6/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALBO
Employees
130
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$48.00
High Stock Price Forecast
$59.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+8.7%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

Net Income
$-34,030,000.00
Net Margins
-228.51%
Pretax Margin
-235.11%

Debt

Sales & Book Value

Annual Sales
$40.58 million
Book Value
$9.11 per share

Miscellaneous

Free Float
19,273,000
Market Cap
$913.91 million
Optionable
Optionable
Beta
1.03

Social Links


Key Executives

  • Ronald H. W. Cooper
    President, Chief Executive Officer & Director
  • Simon John HarfordSimon John Harford
    Chief Financial Officer & Treasurer
  • Jan Peter Mattsson
    Chief Scientific Officer, Managing Director-Sweden
  • Joan Connolly
    Chief Technology Officer
  • Paul D. Streck
    Chief Medical Officer













ALBO Stock - Frequently Asked Questions

Should I buy or sell Albireo Pharma stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ALBO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALBO, but not buy additional shares or sell existing shares.
View ALBO analyst ratings
or view top-rated stocks.

What is Albireo Pharma's stock price forecast for 2023?

7 brokers have issued 12-month price objectives for Albireo Pharma's shares. Their ALBO share price forecasts range from $42.00 to $59.00. On average, they anticipate the company's share price to reach $48.00 in the next year. This suggests a possible upside of 8.7% from the stock's current price.
View analysts price targets for ALBO
or view top-rated stocks among Wall Street analysts.

How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported $2.90 EPS for the quarter, beating the consensus estimate of ($0.38) by $3.28. The biopharmaceutical company had revenue of $3.66 million for the quarter, compared to analyst estimates of $22.33 million. Albireo Pharma had a negative net margin of 228.51% and a negative trailing twelve-month return on equity of 97.13%. During the same quarter last year, the business earned ($1.96) earnings per share.

What ETF holds Albireo Pharma's stock ?

AltShares Event-Driven ET holds 415 shares of ALBO stock, representing 0.59% of its portfolio.

What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Who are Albireo Pharma's major shareholders?

Albireo Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include GW&K Investment Management LLC (0.01%), Susquehanna International Group LLP (0.00%), Group One Trading L.P. (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Jan Mattsson, Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford.
View institutional ownership trends
.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $44.15.

How much money does Albireo Pharma make?

Albireo Pharma (NASDAQ:ALBO) has a market capitalization of $913.91 million and generates $40.58 million in revenue each year. The biopharmaceutical company earns $-34,030,000.00 in net income (profit) each year or ($6.72) on an earnings per share basis.

How many employees does Albireo Pharma have?

The company employs 130 workers across the globe.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The official website for the company is www.albireopharma.com. The biopharmaceutical company can be reached via phone at (857) 254-5555, via email at shareholders@biodel.com, or via fax at 203-796-5001.

This page (NASDAQ:ALBO) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -